CLOFAZIMINE drug for treatment of Leprosy, which had been in short supply in the Indian market for several months, is now “not available” with the situation turning into crisis over the past 3 months.
Fearing the Worst for their patients, doctors have written to the Health Ministry for urgent intervention and immediate restoration of medicine’s supply in the private sector.
India’s report more than 1,25,000 new patients of Leprosy every year. These official numbers apart, another 50,000 to 100,000 patients of Leprosy are seen at the private clinics of dermatologist all over India. Alternate three drugs regiments without Clofazimine are very costly and not often not feasible. Leprosy is still dreaded disease with potential risk of Transmission.
According to World Health Organisation (WHO). The Leprosy is endemic in several states and union territories of India with the annual case detection rate of 4.56 per 10000 population.
Clofazimine in is needed not just for therapy or cure for leprosy but also for controlling a cute exacerbations of this disease which occur frequently.
The prevalence rate of Leprosy is 0.4 per 10000 population in the country. Of the new cases detected during 2020 and 2021, 58.1 percentage were multi bacillary, 39% were women, 5.8% for children less than 14 years of age, and 2.41% has visible deformities the rate visible deformities was 1.1 million population.
Clofazimine has shown activity against multi drug resistance tuberculosis and has been recommended by WHO to treat drug resistance the association.
💫FOLLOW US FOR MORE UPDATES. ❌WE DO NOT HAVE IRRITATING AND SPAMMY NEWSLETTERS. ✅EVERYTHING IS AND WILL BE FREE FOREVER. SEE YOU AGAIN IN YOUR STORIES AND FEED 🙂
